Background Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizumab has improved the outcome, however, its efficacy varies among patients and its discontinuation is debated. Methods To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormalities and/or triggers at onset in 4 categories: (1) primary (complement abnormality without trigger), (2) secondary (trigger without complement abnormality), (3) combined (trigger and complement abnormality), (4) idiopathic (no trigger, no complement abnormality). Response to treatment was evaluated by comparing the response to eculizumab with that of conventional therapy. Short- and long-term outcomes were evaluated with the relapse rate after discontinuation of C5-inhibition. Results Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazard ratio 0.25, 95% confidence interval: 0.10-0.80). The excellent global response was driven by the primary and combined groups (89.8% vs 54.0% and 89.3% vs 54.2%, respectively). The relapse rate following discontinuation of the C5-inhibitor was as high as 66.7% in the primary group, 18.7% in the combined, and 0% in the secondary and idiopathic groups. Conclusions Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed in the secondary and idiopathic forms.[GRAPHICS]

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition / G. Ardissino, D. Cresseri, M.C. Mancuso, V. Capone, L. Porcaro, V. Amico, M. Tangredi, E. Grovetti, S. Griffini, G. Castellano, G. Montini, D. Consonni, M. Cugno, M. Domenico, Z. Marco, V. Luca, V. Giuseppe, V. Enrico, V. Marta, V. Simona, V. Paolo, V. Pellu, T. Martina, T. Silvia, T. Laura, T. Francesco, T. Chiara, T. Lorella, T. Aristide, T. Sara, T. Monica, T. Elisabetta, S. Tiziana, S. Chiara, S. Giuseppe, S. Fabian, S. Chiara, S. Paola, S. Laura, R. Rodolfo, R. Roberto, R. Evangeline, R. Angelo, R. Barbara, R. Angelo, R. Andrea, R. Teresa, P. Leonardo, P. Ilaria, P. Vera, P. Gianmarco, P. Lucia, P. Giulia, P. Giorgio, P. Jacopo, P. Werner, P. Andrea, P. Antonello, P. Giuseppe, P. Fabio, O. Francesco, N. Maria, N. Alessandro, M. Lorenza, N. Valentina, M. Nicola, M. Enrico, M. Tommaso, M. Cristina, M. Sabrina, M. Concetta, M. Alessandra, M. Florjan, M. Marco, M. Laura, M. Verna, M. Sarah, M. Jacopo, M. Silvio, M. Rita, M. Carmelita, M. Annunziata, L. Selena, L. Scola, I. Alessandro, I. Francesco, G. Gina, G. Mario, G. Fabio, G. Giovanni, G. Andrea, F. Lucrezia, F. Riccardo, F. Maria, F. Domenico, F. Angelo, F. Roberta, F. Luca, D. Vecchio, D. Nunzia, D. Philippis, D. Biase, D. Delia, D. Marco, C. Olga, C. Raffaella, C. Luigia, C. Ciro, C. Giacomo, C. Calogero, C. Doriana, C. Francesco, C. Alessandro, C. Nicola, C. Donatella, C. Aldo, C. Alessandra, C. Leonardo, C. Valeria, B. Alessandro, B. Maurizio, B. Brigida, B. Alessandra, B. Maria, B. Bruno, A. Alice, A. Karen, A. Carlo, A. Alessandro, A. Barbara. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1724-6059. - 37:4(2024 May), pp. 1017-1026. [10.1007/s40620-023-01873-9]

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition

G. Castellano;G. Montini;M. Cugno;
2024

Abstract

Background Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizumab has improved the outcome, however, its efficacy varies among patients and its discontinuation is debated. Methods To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormalities and/or triggers at onset in 4 categories: (1) primary (complement abnormality without trigger), (2) secondary (trigger without complement abnormality), (3) combined (trigger and complement abnormality), (4) idiopathic (no trigger, no complement abnormality). Response to treatment was evaluated by comparing the response to eculizumab with that of conventional therapy. Short- and long-term outcomes were evaluated with the relapse rate after discontinuation of C5-inhibition. Results Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazard ratio 0.25, 95% confidence interval: 0.10-0.80). The excellent global response was driven by the primary and combined groups (89.8% vs 54.0% and 89.3% vs 54.2%, respectively). The relapse rate following discontinuation of the C5-inhibitor was as high as 66.7% in the primary group, 18.7% in the combined, and 0% in the secondary and idiopathic groups. Conclusions Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed in the secondary and idiopathic forms.[GRAPHICS]
C5inhibition; Complement abnormalities; Complement dysregulation; aHUS
Settore MEDS-20/A - Pediatria generale e specialistica
mag-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
s40620-023-01873-9.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1116151
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact